Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Phase II Open-label Study of Subcutaneous CPG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00824733
• Other study ID #: OSU-08153
• Secondary ID: NCI-2011-03157
• Status: Terminated
• Phase: Phase 2
• First received: January 16, 2009
• Last updated: December 9, 2015
• Start date: February 2009
• Est. completion date: April 2014

Study information

• Verified date: December 2015
• Source: Ohio State University Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Biological therapies, such as agatolimod, may stimulate the immune system in different ways and stop tumor cells from growing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving agatolimod together with trastuzumab may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving agatolimod together with trastuzumab works in treating patients with locally advanced or metastatic breast cancer.

Description:

OBJECTIVES:

Primary

• To evaluate the progression-free survival of patients with HER2-overexpressing locally advanced or metastatic breast cancer treated with trastuzumab (Herceptin®) and agatolimod sodium.

Secondary

• To determine if agatolimod sodium augments antibody-mediated cytoxicity (ADCC) against trastuzumab-coated target cells by evaluating the ability of patient immune-effector cells to conduct ADCC and produce interferon gamma.

OUTLINE: This is a multicenter study.

Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Patients also receive agatolimod sodium subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Blood samples are collected periodically for correlative laboratory studies. Samples are analyzed for antibody-mediated cytotoxicity (ADCC) by chromium-release assay; IFN-γ production and quantification by flow cytometry and reverse transcriptase-polymerase chain reaction (RT-PCR); and levels of cytokines (IFN-γ and TNF-α) by ELISA.

After completion of study therapy, patients are followed periodically.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: April 2014
• Est. primary completion date: February 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed breast cancer

• Locally advanced or metastatic disease

• HER2-overexpressing tumor, defined as 3+ overexpression by IHC and/or HER2 amplified by FISH

• Non-measurable disease allowed

• Achieved partial response, complete response, or stable disease (i.e., no disease progression for = 12 weeks) while on trastuzumab (Herceptin®) and chemotherapy, hormonal therapy alone, or trastuzumab alone

• Last dose of trastuzumab must have been administered within the past 16 weeks

• No unstable brain metastases

• Patients with brain metastases are eligible provided they have been stable for = 1 month after surgery or radiotherapy/radiosurgery AND off corticosteroids and anticonvulsants for = 4 weeks

• Hormone receptor status unspecified

PATIENT CHARACTERISTICS:

• ECOG(Eastern Cooperative Oncology Group)performance status (PS) 0-2 (Karnofsky PS 70-100%)

• Absolute neutrophil count = 1,500/mm³

• Hemoglobin > 8 g/dL (transfusion/epoetin alfa allowed)

• Platelet count = 100,000/mm³

• Total bilirubin < 1.5 times upper limit of normal (ULN)

• AST and ALT = 2.5 times ULN (= 5.0 times ULN if known liver metastases)

• Creatinine < 2 mg/mL

• Ejection fraction = 50% by echocardiogram or MUGA

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception before, during, and for = 3 months after completion of study treatment

• No ongoing or active infection requiring oral or IV antibiotics

• No known autoimmune disorders or antibody-mediated disorders

• No known HIV positivity

• No known history of hepatitis B or C (active and/or previously treated)

• No other malignancies within the past 5 years except nonmelanoma skin cancer or cervical cancer in situ

• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• More than 12 weeks since prior chloroquine

• More than 4 weeks since prior growth factors

• More than 4 weeks since prior systemic corticosteroids

• More than 4 weeks since prior chemotherapy, radiotherapy, or monoclonal antibody therapy (except trastuzumab)

• No prior agatolimod sodium

• No prior allogeneic stem cell transplantation

• No prior continuous treatment with single-agent trastuzumab for > 6 months

• No more than 3 prior chemotherapy regimens for metastatic breast cancer

• Any number of prior hormonal therapies allowed

• No other concurrent investigational agents or monoclonal antibodies

• No other concurrent anticancer agents or therapies

• Concurrent bisphosphonates for skeletal metastasis allowed

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Trastuzumab
IV at 2 mg/kg over 30 minutes on day 1 of each weekly cycle. Patients who have not received trastuzumab for 4 weeks or more will receive a loading dose of 4 mg/kg over 90 minutes day 1 of the first cycle. The dose of trastuzumab will be based on the patient's actual weight at the start of each 4 week treatment cycle.
• PF03512676
Patients also receive PF03512676 subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses.

Other:
• Correlative Studies
Blood for performing the correlative studies will be drawn on week 1, 2, 6, 12 and 18.

Locations

Country	Name	City	State
United States	The Ohio State University Wexner Medical Center	Columbus	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Bhuvaneswari Ramaswamy	Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PF-03512676 Augments Antibody Mediated Cytoxicity (ADCC)Against Trastuzumab-coated Target Cells in Metastatic HER2 Overexpressing Breast Cancer.		up to 18 weeks	Yes
Secondary	Progression-free Survival for Patients With Metastatic Breast Cancer That Are Receiving Trastuzumab Plus PF-03512676	Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions	up to 18 weeks	No
Secondary	Combination of PF-03512676 and Trastuzumab Induces MIP-1 (Macrophage Inflammatory Protein 1), MCP-1 (Monocyte Chemoattract Protein 1) and RANTES.		up to 18 weeks	No

External Links

•   Jamesline